Cargando…

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis

INTRODUCTION: The biosimilar product Inflectra(®) has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaniewska, Magdalena, Moniuszko, Andrzej, Rydzewska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672704/ https://www.ncbi.nlm.nih.gov/pubmed/29123576 http://dx.doi.org/10.5114/pg.2017.70468

Ejemplares similares

Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques
por: Fang, Jing, et al.
Publicado: (2016)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study
por: Moniuszko, Andrzej, et al.
Publicado: (2017)

Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease
por: Smits, Lisa J. T., et al.
Publicado: (2017)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Biomarkers in management of inflammatory bowel disease
por: Moniuszko, Andrzej, et al.
Publicado: (2013)

Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Working Group Guidelines on the nursing roles in caring for patients with Crohn's disease and ulcerative colitis in Poland
por: Golik, Magdalena, et al.
Publicado: (2014)

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review
por: Tieu, Carolyn, et al.
Publicado: (2018)

Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice
por: Tulewicz-Marti, Edyta, et al.
Publicado: (2017)

Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
por: Lewandowski, Konrad, et al.
Publicado: (2021)

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?
por: Lewandowski, Konrad, et al.
Publicado: (2021)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Selected Aspects of Nutrition in the Prevention and Treatment of Inflammatory Bowel Disease
por: Panufnik, Paulina, et al.
Publicado: (2022)

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab
por: Alexeev, Sergey M., et al.
Publicado: (2020)

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
por: Stroyakovskiy, Daniil L., et al.
Publicado: (2022)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Skin and gastrointestinal symptoms in COVID-19
por: Ciechanowicz, Piotr, et al.
Publicado: (2020)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Szczubełek, Martyna, et al.
Publicado: (2021)

Reply to van Lingen et al. Comment on “Szczubełek et al. Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients. Nutrients 2021, 13, 4112”
por: Szczubełek, Martyna, et al.
Publicado: (2022)

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
por: Sullivan, Emma, et al.
Publicado: (2017)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis
por: Gheorghe, Cristian, et al.
Publicado: (2019)

Successful treatment of an enterovesical fistula due to Crohn’s disease with stem cell transplantation: a case report
por: Moniuszko, Andrzej, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cb1v50c08g2011l1m2us2pvvbm